Skip To Main Content
Ying Zheng on Muck Rack

Ying Zheng

As seen in: Color Research & Application, Emerging Infectious Diseases Journal, Nature, Wiley Online Library, Applied Health Economics and Health Policy, PLOS ONE, Administrative Sciences, BMJ Open, Frontiers, Frontiers in Immunology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Import penetration and corporate misconduct: a natural experiment

|
By Ying Zheng, Christopher Dupuis
| Dialnet - Universidad de La Rioja
IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Open in Who Shared View Duplicates (484) Issue with article?

The Construction of a Mezzo-Soprano Pedagogical Framework from a Cultural Adaptation Perspective-A Grounded Theory Analysis Based on the Experiences of Mezzo-Soprano Educators and Students from China and the West

|
By Ying Zheng
| Dialnet - Universidad de La Rioja
Against the backdrop of deepening global integration in music education, how to scientifically introduce and effectively integrate Western bel canto mezzo-soprano pedagogy into China’s indigenous vocal system has become a significant academic concern.
Open in Who Shared Issue with article?

Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial

|
By Rui Feng, Ping Liang, Yajing Wang, Dong Li, Huixian Jia, Ying Zheng, Liman Huo, Qi Lv
| Frontiers in Public Health Verified
Abstract Objective: To assess the cost-effectiveness of tremelimumab plus durvalumab [the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen] versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma in China using 5-year follow-up data from the HIMALAYA trial. Methods: A three-state partitioned survival model comprising progression-free survival, progressed disease, and death was developed from the perspective of the Chinese healthcare system.
Open in Who Shared Issue with article?
See all 169 licensed articles (179 Total)